RZLT vs. ARQT, SPRY, SDGR, OCUL, VERA, BHVN, EVO, ETNB, JANX, and ANIP
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), Biohaven (BHVN), Evotec (EVO), 89BIO (ETNB), Janux Therapeutics (JANX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry.
Rezolute vs. Its Competitors
Rezolute (NASDAQ:RZLT) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.
In the previous week, Arcutis Biotherapeutics had 10 more articles in the media than Rezolute. MarketBeat recorded 13 mentions for Arcutis Biotherapeutics and 3 mentions for Rezolute. Rezolute's average media sentiment score of 0.58 beat Arcutis Biotherapeutics' score of 0.54 indicating that Rezolute is being referred to more favorably in the media.
Rezolute has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -60.95%. Rezolute's return on equity of -70.09% beat Arcutis Biotherapeutics' return on equity.
Rezolute has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.
Rezolute has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
Rezolute presently has a consensus target price of $11.83, indicating a potential upside of 131.57%. Arcutis Biotherapeutics has a consensus target price of $18.80, indicating a potential upside of 22.08%. Given Rezolute's stronger consensus rating and higher possible upside, equities research analysts plainly believe Rezolute is more favorable than Arcutis Biotherapeutics.
83.0% of Rezolute shares are owned by institutional investors. 18.4% of Rezolute shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Rezolute beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
This page (NASDAQ:RZLT) was last updated on 7/16/2025 by MarketBeat.com Staff
